CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

Introduction: Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, scalability in MSC production, timing and technique...

Description complète

Détails bibliographiques

Auteurs principaux:	Sohsuke Meshitsuka, Ryo Ninomiya, Tokiko Nagamura-Inoue, Takashi Okada, Muneyoshi Futami, Arinobu Tojo
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2022-12-01
Collection:	Regenerative Therapy
Sujets:	UC-MSCs AAV CRISPR/Cas9 HLA-G Allogenic rejection
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2352320422000955
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!